AMIVANTAMAB
amivantamab 350 mg/7 mL injection, 7 mL vial
AMIVANTAMAB (14807H)
14807H
Manner of administration:Injection
Restriction
Indication: Stage IIIB/ IIIC (locally advanced) or Stage IV (metastatic) non-small cell lung cancer
(NSCLC)
Treatment phase: Continuing treatment
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 2100 mg | # of repeats: 7 | DPMA: $9,165.58 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Rybrevant
(amivantamab 350 mg/7 mL injection, 7 mL vial)
|
||||